The plaintiff filed a motion for a new trial, arguing that, “At a minimum, the verdict shows confusion and lack of ...

Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant ...

The FDA’s decision marks J&J's Spravato as the first monotherapy for adults with treatment-resistant depression.

Share on Facebook Share on Twitter Jason Aldean is hitting the road in 2025. He just announced his Full Throttle Tour. Jason ...

Share on Facebook Share on Twitter President Trump is so busy rewriting the U.S. Government it feels he’s at risk for carpal ...

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...

The accelerating sales growth of Johnson & Johnson's Spravato could go up yet another gear after the FDA approved a third ...

Johnson & Johnson's stock reversed gains made early Wednesday immediately after earnings were released, after the medical technology and drug company beat estimates for the fourth quarter, but offered ...

Johnson & Johnson's stock (JNJ) rose 1.9% early Wednesday, after the medical tech and drug company posted better-than-expected earnings for the fourth quarter, offsetting mixed guidance. The company ...

J&J's depression drug Spravato hits $1B in 2024 sales, up 56% from 2023, with expanded label approval and 140,000+ patients ...